一线化疗方案对青年女性晚期胃癌的临床疗效及其与降钙素原水平的相关性研究

Clinical efficacy of first-line chemotherapy regimen in young female patients with advanced gastric cancer and its correlation with procalcitonin level

目的探讨不同一线化疗方案对于青年女性晚期胃癌的临床效果及其与降钙素原水平的相关性。方法选取本院2016年3月至2017年2月收治的青年女性晚期胃癌患者86例为研究对象,采用随机数表法将其分为观察组(氟尿嘧啶+顺铂+紫杉醇治疗)和对照组(氟尿嘧啶+顺铂治疗),每组各43例。比较两组患者的临床疗效、不良反应发生情况、治疗前后降钙素原水平变化情况,并采用皮尔逊相关系数明确降钙素原水平与患者的疾病进展和死亡的相关性。结果两组患者治疗有效率比较无统计学意义(P>0.05),观察组患者无进展生存时间显著长于对照组(P<0.05)。两组患者不良反应发生率比较差异均无统计学意义(均P>0.05)。观察组患者化疗结束时的血清降钙素原水平显著低于对照组(P<0.05)。皮尔逊相关系数显示,患者降钙素原水平与疾病进展存在相关性(r=0.789,P<0.001)。偏相关分析显示,患者降钙素原水平与疾病进展存在相关性(r=0.342,P=0.001)。结论青年女性晚期胃癌患者应用氟尿嘧啶+顺铂+紫杉醇联合化疗能够延长其无进展生存期,且患者能够耐受,联合化疗能够降低患者治疗期间的降钙素原水平,但应常规监测患者化疗后的降钙素原水平。

Objective To investigate the correlation between clinical effect and procalcitonin level in young female patients with advanced gastric cancer treated with different first-line chemotherapy regimen.Method 86 young female patients with advanced gastric cancer admitted in our hospital from March 2016 to February 2017 were selected as the study subjects,and they were divided into observation group(Fluorouracil+Cisplatin+Paclitaxel chemotherapy regimen)and control group(Fluorouracil+Cisplatin chemotherapy regimen)by random number table method,43 cases in each group.The clinical efficacy,incidence of adverse reactions,procalcitonin level changes before and after treatment were compared between the two groups,and Pearson correlation coefficients were used to determine the correlation between procalcitonin levels and disease progression and death in patients.Result There was no significant difference in the response rate between the two groups(P>0.05).The progression-free survival of observation group was significantly longer than that of control group(P<0.05).At the end of chemotherapy,the serum procalcitonin level in observation group was lower than that in control group(P<0.05).Pearson correlation coefficient showed that procalcitonin level was correlated with disease progression(r=0.789,P<0.001).Partial correlation analysis showed that the correlation between procalcitonin and disease progression remained(r=0.342,P=0.001).Conclusion Fluorouracil+Cisplatin+Paclitaxel can extend the progression-free survival of young female patients with advanced gastric cancer,and the patients can tolerate it,combined chemotherapy can reduce the level of procalcitonin during treatment,so the level of procalcitonin should be routinely monitored after chemotherapy.